Melbourne, Sep 23, 2008 AEST (ABN Newswire) - Australia's regenerative medicine company, Mesoblast Limited (ASX:MSB)(PINK:MBLTY), today announced that its commercial and business activities are being highlighted at The World Stem Cell Summit in Wisconsin, United States, on 23 September 2008.
Executive Director, Professor Silviu Itescu, is a featured speaker at the Summit's investor session entitled "Commercialisation of Stem Cells and Market Trends". A central theme in the presentation is the significant commercial advantage inherent to Mesoblast's allogeneic, or "of-the-shelf", business model for its proprietary adult stem cell technology platform.
A further key focus is on Mesoblast's enhanced business opportunities in the bone repair markets in view of recent concerns by the US Food and Drug Administration (FDA) on the use of Bone Morphogenetic Protein for fusion of the cervical spine. Mesoblast's exceptional safety record and strong clinical results in the fields of spinal fusion and fracture repair serve to highlight the company's competitive advantages in these large global markets.
Mesoblast is one of only a handful of stem cell companies to be featured at The World Stem Cell Summit. According to The World Stem Cell Summit organiser, the US Genetics Policy Institute, the meeting is the pre-eminent gathering for the global stem cell community, bringing together industry leaders, policy-makers, regulators, patient advocates, legal experts, investors, philanthropists and researchers to chart the future of regenerative medicine.
Contact
Julie Meldrum
Corporate Communications Director
Mesoblast Limited
T: + 61 (03) 9639 6036
E: julie.meldrum@mesoblast.com
W: www.mesoblast.com
| ||
|
